Eli Lilly: A Strong Buy Amidst Obesity Treatment Market …
WEB1 day ago · In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New ...
WEB1 day ago · Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. ... Of course, any negative news regarding GLP-1 side effects or adverse FDA decisions could weigh on this high-P/E ...
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
WEB1 day ago · Eli Lilly's stock trades at a high premium with a price/book ratio of 63.94, raising concerns about overvaluation compared to the sector median of 2.47. Despite strong revenue and earnings growth ...
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints.
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
News Release - Eli Lilly and Company
WEBNov 8, 2023 · Lilly is putting a commercial savings card program in place that will help people who may benefit from Zepbound better access it. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.